PDCD1 and renal cell adenocarcinoma: This is because the blocking of PD-1 or PD-L1 molecules exhibited higher efficacy and lower toxicity for several types of human cancers, including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC).